Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases
The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).
NSCLC
DRUG: Temozolomide
objective response rate, 1 month post procedure|Time to central nervous system progress which was confirmed by MRI, 1 to 24 months post procedure
The Quality of Life, 0 to 24 months post procedure|Overall Survival, 1 to 24 months post procedure|Toxicity as measured by CTCAE V4.0, 0 to 24 months post procedure
The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).